Neil's Feed
Jul 27, 2015
via Breakingviews

Teva exits Mylan mess with $40.5 bln Allergan deal

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Teva has found a neat exit from its Mylan mess. The Israeli pharmaceutical firm has been locked in a bitter battle to take over the Dutch drugmaker. Now it has agreed to buy the generic business from Allergan for $40.5 billion. The swap makes sense.

Jul 10, 2015
via Breakingviews

Tsipras U-turn only lowers short-term Grexit risks

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alexis Tsipras’ U-turn only lowers Grexit risks in the short term. Greece’s latest bailout plan accepts most of what its July 5 referendum rejected. The 61.3 percent of voters who chose “Oxi” will be a little confused.

Jul 10, 2015
via Breakingviews

Tsipras U-turn only lowers short-term Grexit risks

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alexis Tsipras’ U-turn only lowers Grexit risks in the short term. Greece’s latest bailout plan accepts most of what its July 5 referendum rejected. The 61.3 percent of voters who chose “Oxi” will be a little confused.

May 21, 2015
via Breakingviews

Renzi is still dodging big Italian pension fight

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Matteo Renzi seems to have won a tricky pension battle. But Italy’s prime minister has only skirmished with the real enemy.

May 21, 2015
via Breakingviews

Renzi is still dodging big Italian pension fight

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Matteo Renzi seems to have won a tricky pension battle. But Italy’s prime minister has only skirmished with the real enemy.

May 8, 2015
via Breakingviews

Monsanto heaps pressure on Syngenta

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Monsanto is heaping pressure on Syngenta. A $45 billion takeover proposal from the world’s biggest provider of seeds to farmers to the top seller of crop-protection chemicals was quickly rejected as too cheap and too risky. The Swiss target has a point on the difficulties, but needs to lay out just how it will create more standalone value.

May 8, 2015
via Breakingviews

Monsanto heaps pressure on Syngenta

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Monsanto is heaping pressure on Syngenta. A $45 billion takeover proposal from the world’s biggest provider of seeds to farmers to the top seller of crop-protection chemicals was quickly rejected as too cheap and too risky. The Swiss target has a point on the difficulties, but needs to lay out just how it will create more standalone value.

Apr 30, 2015
via Breakingviews

Renzi’s Italian gamble is worth taking

Photo

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Matteo Renzi is risking chaos for the sake of stability. Italy’s premier is using confidence votes to ram though electoral reform. It’s a controversial move, which could bring the government down. Yet the cause is worthy.

Apr 30, 2015
via Breakingviews

Renzi’s Italian gamble is worth taking

Photo

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Matteo Renzi is risking chaos for the sake of stability. Italy’s premier is using confidence votes to ram though electoral reform. It’s a controversial move, which could bring the government down. Yet the cause is worthy.

Apr 15, 2015
via Breakingviews

Agnellis pay up to claim mini-Buffett status

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The Agnellis are paying up to do an impression of Warren Buffett. The Italian family’s holding company Exor is offering $6.4 billion to buy PartnerRe out of a merger with fellow Bermudan insurer Axis Capital Holdings. If the Fiat owners can pull it off, they could use Berkshire Hathaway-style stable cash flows to fund further acquisitions. They’re even using Buffett’s adviser of choice, Byron Trott, on the deal.